Alpha Tau Announces Cornerstone Interim Data Across Multiple Clinical Trials to be Shared at R&D Update Day
Provided By GlobeNewswire
Last update: Jan 27, 2025
- High disease control rate and strong interim safety results observed in pancreatic cancer patients across three trials exploring the use of Alpha DaRT® -
Read more at globenewswire.comNASDAQ:DRTSW (6/26/2025, 12:39:15 PM)
0.2498
0 (-0.04%)
NASDAQ:DRTS (6/26/2025, 1:15:42 PM)
3.04
+0.04 (+1.33%)
Find more stocks in the Stock Screener
